Paclitaxel nanoparticles

Koziara, J. M. Whisman, X. R. Xseng, M. X Mumper, R. J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 2006, 112, 312-319. 

Abraxane Albumin-bound paclitaxel nanoparticle Metastatic breast cancer... 

M.D. Chavanpatil, Y. Patil, and J. Panyam. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm. 320 150-156 (2006). 

ABI-007 (Abraxane) Albumin-coated nanoparticle paclitaxel tubulin inhibitor Breast cancer Randomized Phase II trial... 

O Shaughnessy, J.A. et al.. Weekly nanoparticle albumin paclitaxel (Abraxane) results in longterm disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Research and Treatment, In Lippman, M.E., Editor-in-Chief, Special Issue 27th Annual San Antonio Breast Cancer Symposium, Kluwer Academic Publishers, Dordrecht, Vol. 88, Suppl. 1, 2004, Abstr. 1070. 

Stevens PJ, Sekido M, Lee RJ. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 2004 21 2153. 

Chen D.B. et al.. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel, Chem. Pharm. Bull., 49, 1444, 2001. 

K. Kataoka, andT. Kakizoe. 2005. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extendh vivo antitumour activity and reduce the neurotoxicity of paclitafel.J. Cancer 92 1240-1246. 

More recently, with sirolimus analogs such as everolimus or with the use of nanoparticles of paclitaxel, a significant... 

Kolodgie FD, John M, Khurana C, et al, Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel, Circulation 2002 106 ... 

Fonseca, C., S. Simoes, et al. (2002). Paclitaxel-loaded PLGA nanoparticles preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83(2) 273-286. 

Calo, S., Bonaccorsi, A., Mattavelli, F., Costa, L., Mariani, L., and Cantu, G. (2003), A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue Preliminary findings, Am. J. Roentgenol., 181(1), 253-260. 

Potineni, A., Lynn, D. M., Langer, R., and Amiji, M. M. (2003), Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery, / Controlled Release, 86(2-3), 223-234. 

Dong, Y., and Feng,S.S. (2006),Nanoparticles of poly(D,L-lactide)/methoxypoly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel, J. Biomed. Mater. Res. A, 78(1), 12-19. 

Sahoo, S. K., Ma, W., and Labhasetwar, V. (2004), Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer, Int. J. Cancer, 112(2), 335-340. 

Drug-loaded nanoparticles were also evaluated for their safety and efficacy. Paclitaxel-encapsulated 6-O-CAPRO-p-CD nanospheres and nanocapsules were evaluated for their physical stability in a one-month period in aqueous dispersion form with repeated particle size and zeta potential measurements and AFM imaging to evaluate recrystallization in aqueous medium. Paclitaxel-loaded amphiphilic CD nanoparticles were found to be physically stable for a period of one month whereas recrystallization occurs within minutes when diluted for intravenous (IV) infusion [85], Finally, paclitaxel-loaded amphiphilic nanoparticles were demonstrated to show similar anticancer efficacy against MCF-7 cells when compared to paclitaxel solution in a cremophor vehicle [85],... 

Abraxane is a successful paradigm of nanoparticle application. It is an albumin nanoparticle loading paclitaxel developed by American Pharmaceutical Partners (APP) and American BioScience. The outstanding advantage of Abraxane is no significant side effects, not like the traditional paclitaxel preparation with Cremo-phor EL (polyethoxylated castor oil) and ethanol. More nanoparticle products will reach the market in the future. 

PEG-coated (polycyanoacrylate) nanoparticles Paclitaxel Transferrin S-180 bearing mice ... 

Yan, Z. Li, Y. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery PEG coated... 

A novel nanoparticulate lipid-based carrier system was developed by Mumper et al. at the University of Kentucky. ° This carrier system is composed of a lipophilic-emulsifying wax such as cetyl alcohol/ polysorbate 60 and other surfactants such as Brij 72, Brij 78, and Tween 80. The nanoparticles were formed through a warm microemulsion technique where encapsulates have included paclitaxel and plasmid DNA. The emulsification process is spontaneous, and cooling of the emulsion causes solidification of the nanoparticle-containing drug. This novel carrier has shown high efficiency in drug delivery across the blood-brain barrier. 

Ibrahim, N.K. Desai, N. Legha, S. Soon-Shiong, P. Theriault, R.L. Rivera, E. Esmaeli, B. Ring, S.E. Bedikian, A. Hortobagyi, G.N. Ellerhorst, J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 2002, 8 (5), 1038-1044. 

In a variation of this theme, the stabilizer used is albumin. This technology results in an amorphous nanoparticle form of the drug coated by albumin, and having a size of about 100-200 nm. Drugs prepared by this technology have been tested by intravenous, intra-arterial, inhalational, oral, and topical administration. In the case of i.v. paclitaxel, the albumin is said to result in an increased and prolonged intracellular availability of the drug. ... 

Fig. 10.16 Tumor pacUtaxel concentrations upon intravenous administration to SKOV-3 human ovarian adenocarcinoma bearing nude mice. Paclitaxel was administered intravenously in aqueous solution, poly(ethylene oxide)-modified polycaprolactone (PCL) nanoparticles, or poly(ethylene oxide)-modified poly(P-amino ester) (PbAE) nanoparticles, (reproduced from [212], with permission from Springer)...

---